“…Tumor-associated neutrophils are often considered as pro-tumor “N2” polarized neutrophils (Fridlender and Albelda, 2012) and the immunosuppressive granulocytic-subtype of myeloid derived suppressor cells also possess a similar phenotype (Gabrilovich et al, 2012). However, there are examples where neutrophils are required for antibody therapeutic effects in xenograft tumor control studies (Eisenbeis et al, 2003; Schneider-Merck et al, 2010; Siders et al, 2010). In fact, it seems intuitive to utilize the underappreciated neutrophil to mount an anti-tumor response given that they are the most abundant of circulating leukocytes, and in other forms of immune challenge, neutrophils are the first responders, inducing massive cell-killing.…”